Celularity Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated February 12, 2025, reports that Celularity Inc. (CELU) entered into binding term sheets with two major lenders, Resorts World Inc Pte Ltd (RWI) and C.V. Starr & Co., Inc. (Starr). The filings address the extension of forbearance agreements and the restructuring of outstanding debt maturities.
Key Financial Metrics and Debt Structure
The filing details specific debt obligations and new equity commitments:
- RWI Debt: Total principal of $27,000,000 (comprising loans of $6M, $6M, and $15M net of a $3.75M OID). Maturity extended to February 15, 2026.
- Starr Debt: Principal of $5,000,000 (net of $100,000 OID). Maturity extended to February 15, 2026.
- Accrued Interest Payments: The Company agreed to pay approximately $1.3 million to RWI and $0.8 million to Starr using proceeds from its next registered public offering.
- Equity Issuance: New five-year warrants to be issued: 500,000 shares to RWI and 100,000 shares to Starr.
Note: This filing does not provide revenue, profit, cash flow, or margin data.
Material Changes and Restructuring Terms
Material changes involve the extension of loan maturities and the repricing of existing warrants:
- Maturity Extension: Both RWI and Starr loans, previously subject to forbearance agreements dated March 13, 2024, are extended to February 15, 2026.
- RWI Warrant Repricing: Existing warrants will be repriced to 90% of the closing stock price on July 24, 2025, with a floor of $1.50. If the 90% calculation falls below $1.50, the price adjusts to 180% of the closing price until it meets the $1.50 floor.
- Starr Warrant Repricing: Existing warrants will be repriced to 10% less than the closing stock price on the amendment date, with a floor of $1.50.
- New Warrants: New warrants issued to both lenders will have exercise prices subject to the same $1.50 floor and specific pricing formulas tied to future stock prices.
Outlook, Risks, and Contingencies
The Company's ability to satisfy the cash interest payment obligations ($2.1 million total) is contingent upon the successful completion of its next registered public offering. The filing indicates the Company was previously in default or at risk of default, necessitating the forbearance extensions. The repricing of warrants introduces potential dilution risks dependent on the Company's stock price performance in mid-2025.
Investor Verification Checklist
- Verify the status and expected timeline of the Company's "next registered public offering" required to fund the $2.1 million interest payment.
- Monitor the stock price on July 24, 2025, to determine the final exercise price of the new and repriced RWI warrants.
- Confirm the exact date of the "Starr Amendment" to calculate the exercise price for Starr's new and repriced warrants.
- Review the full text of the Binding Term Sheets (Exhibits 10.1 and 10.2) for additional covenants or default triggers not summarized here.